Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Zymeworks Inc. - Common Stock
(NQ:
ZYME
)
12.55
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Zymeworks Inc. - Common Stock
Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)
March 10, 2025
Via
Benzinga
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
March 06, 2025
Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.
Via
Benzinga
Topics
Earnings
Exposures
Financial
Earnings Scheduled For March 5, 2025
March 05, 2025
Via
Benzinga
Deep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)
December 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 23, 2025
Via
Benzinga
Zymeworks in Focus for Insider Activity: Catalysts Ahead
January 10, 2025
Zymeworks' insider EcoR1 Capital is buying shares ahead of expected catalysts in 2025 that could drive the stock price to multiyear highs.
Via
MarketBeat
Exposures
Product Safety
In-Depth Examination Of 9 Analyst Recommendations For Zymeworks
November 22, 2024
Via
Benzinga
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
November 21, 2024
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.
Via
Benzinga
Exposures
Product Safety
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
November 07, 2024
Via
Benzinga
What Analysts Are Saying About Zymeworks Stock
October 22, 2024
Via
Benzinga
Navigating 6 Analyst Ratings For Zymeworks
June 06, 2024
Via
Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
June 15, 2024
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...
Via
Talk Markets
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.